Assessment Status | Rapid Review Complete |
HTA ID | - |
Drug | Rolapitant |
Brand | Varuby® |
Indication | For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. |
Assessment Process | |
Rapid review commissioned | 15/05/2017 |
Rapid review completed | 12/06/2017 |
Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |